Anthony Means, PhD, Baylor College of Medicine
Dr. Anthony R. Means is a pre-eminent biomedical scientist who studies how calcium participates in the regulation of cell function. He has been interested in the signaling pathways regulated by hormones and growth factors since graduate school where he worked on early actions of estrogen. Following postdoctoral training in Australia where he began investigations on the early actions of FSH in the male he continued this interest as a faculty member at Vanderbilt and Baylor College of Medicine. Close examination of immediate post-receptor signaling led to an appreciation of important roles for Ca2+ and the identification of a Ca2+ receptor that was subsequently christened calmodulin (CaM). Not only was Dr. Means one of the first to recognize the importance of CaM, he is the principle architect of a now central tenant in biology that CaM serves as the primary and ubiquitous receptor for calcium. He was the first to sequence the calmodulin protein, isolate its gene and determine its 3D structure alone and bound to two separate target enzymes.. Currently, he uses mouse models to demonstrate important roles for these protein kinases in human diseases such as cancer, diabetes/obesity and other components of metabolic syndrome. Dr. Means is a distinguished Professor Emeritus at Duke University Medical Center in Pharmacology and Cancer Biology and is now currently a Professor at Baylor College Medicine, Houston, Texas. In Molecular and Cellular Biology.
Eliezer Masliah, MD, Dept. of Neuroscience, UCSD
Eliezer Masliah received his Medical Doctor Degree from the National Autonomous University of Mexico in 1982, after completing a post-graduate residency training in Pathology at the National Institutes of Health in Mexico City in 1986, Dr. Masliah completed a fellowship in Neuropathology and neurodegenerative disorders at the University of California, San Diego in 1989. Dr. Masliah was recruited both by the Departments of Neurosciences and Pathology at the University of California, San Diego where he is currently Tenured Professor, Director of the Laboratory of Experimental Neuropathology and Director of the Autopsy Service at the UCSD-Medical Center. Dr. Masliah has published over 500 original research articles, 50 books chapters and over 10 patents. The laboratory of Dr. Masliah is dedicated at investigating the molecular mechanisms of synaptic degeneration and developing new therapies for neurological disorders such as Alzheimer’s Disease, Parkinson’s Disease, Multiple System Atrophy, HIV dementia and Huntington’s Disease. Dr. Masliah laboratory has developed transgenic mouse models of these neurodegenerative disorders and is actively involved in better understanding the mechanisms of synaptic damage and at developing novel treatments for these devastating disorders including gene therapy, immunotherapy and small molecule approaches to reduce protein misfolding and aggregation.